Stock Scorecard



Stock Summary for Myovant Sciences Ltd (MYOV)

Total Score

9 out of 29

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for MYOV

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for MYOV

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for MYOV

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2

Bonus Criteria for MYOV

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Financial Details for MYOV

Company Overview

Company Name Myovant Sciences Ltd
Country USA
Description Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company is headquartered in London, the United Kingdom.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 9/30/2022
Next Earnings Date 1/24/2023

Stock Price History

Last Day Price 26.79
Last Day Volume 512,818
Average Daily Volume 2,452,902
52-Week High 26.90
52-Week Low 7.67
Last Price to 52 Week Low 249.28 %

Valuation Measures

Trailing PE 0.00
Industry PE 38.49
Sector PE 93.33
5-Year Average PE -9.48
Free Cash Flow Ratio 6.98
Industry Free Cash Flow Ratio 8.26
Sector Free Cash Flow Ratio 37.81
Book Value Per Share Most Recent Quarter 0.19
Price to Book Ratio 70.01
Industry Price to Book Ratio 6.06
Sector Price to Book Ratio 15.40
Price to Sales Ratio Twelve Trailing Months 7.78
Industry Price to Sales Ratio Twelve Trailing Months 67.23
Sector Price to Sales Ratio Twelve Trailing Months 25.28

Share Statistics

Total Shares Outstanding 96,803,000
Market Capitalization 2,593,352,370
Institutional Ownership 39.68 %

Dividends

Ex-Dividend Date
Last Dividend Amount 0.00
Current Dividend Amount 0.00
Dividend Aristocrat? False
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00 %
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00 %
5-Year Average Dividend Yield 0.00 %
5-Year Dividend Payments Count 0
Dividend Payout Ratio 0.00 %

Income Statement

Quarterly Earnings Growth YOY 0.00 %
Annual Earnings Growth 19.27 %
Reported EPS Past Year -0.69
Reported EPS Prior Year -2.21
Net Income Twelve Trailing Months -189,588,000
Net Income Past Year -205,981,000
Net Income Prior Year -255,134,000
Quarterly Revenue Growth YOY 34.60 %
5-Year Revenue Growth 353.69 %

Balance Sheet

Total Cash Per Share 3.84
Total Cash Most Recent Quarter 371,300,000
Total Cash Past Year 434,200,000
Total Cash Prior Year 684,900,000
Net Cash Position Most Recent Quarter 12,600,000
Net Cash Position Past Year 75,500,000
Long Term Debt Past Year 358,700,000
Long Term Debt Prior Year 358,700,000
Total Debt Most Recent Quarter 358,700,000
Equity to Debt Ratio Past Year 0.00
Equity to Debt Ratio Most Recent Quarter 0.00
Current Ratio Most Recent Quarter 1.83
Total Stockholder Equity Past Year 2,000
Total Stockholder Equity Prior Year 2,000
Total Stockholder Equity Most Recent Quarter 2,000

Options

Put/Call Ratio 0.00
Has Options Options Chain
Liquidity Rating

Technical Analysis

MACD 0.50
MACD Signal 0.67
20-Day Bollinger Lower Band 12.10
20-Day Bollinger Middle Band 13.09
20-Day Bollinger Upper Band 14.08
Beta 2.24
RSI 71.35
50-Day SMA 15.76
200-Day SMA 16.51

System

Modified 12/1/2022 8:17:58 PM